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Background. Patients with ESRD have excessive cardiovascular
morbidity and mortality. In postmenopausal women with normal
renal function, estrogen replacement therapy decreases cardiovas-
cular mortality by 50%, in part because of their beneficial effects
on the lipoprotein profile. Because of similarities in the lipopro-
tein profile between healthy, postmenopausal women, and women
with ESRD, we examined the effects of estrogen replacement on
lipoproteins in 11 postmenopausal women with ESRD.
Methods. In a randomized, placebo-controlled crossover study
(8 week treatment arms) using 2 mg daily of oral, micronized
estradiol, 11 postmenopausal women with ESRD were treated.
Neither baseline lipid nor lipoprotein abnormalities were used as
entry criteria for study participation.
Results. Blood estradiol levels were 19 6 4 with placebo and
194 6 67 pg/ml (P 5 0.024) with estradiol treatment. Total HDL
cholesterol concentrations increased from 52 6 19 mg/dl to 61 6
20 mg/dl (16%), with placebo and estradiol treatments, respec-
tively (P 5 0.002). Apolipoprotein A1 increased by 24.6% (P 5
0.0002) with estradiol intervention. HDL2 concentrations were
19 6 13 with placebo and 24 6 16 with estradiol treatment (P 5
0.046). There were no differences in total or LDL cholesterol,
other lipoprotein fractions including Lp(a), and triglycerides with
2 mg daily estradiol treatment. No significant side effects were
observed.
Conclusions. Therefore, using standard dosage regimens for
estrogen replacement therapy in postmenopausal women with
ESRD, HDL cholesterol is increased to an extent that would be
expected to improve their cardiovascular risk profile. Further
studies are needed to assess whether estrogen replacement ther-
apy decreases the incidence or severity of cardiovascular disease
in ESRD patients to a similar degree compared with other
women.
In contrast to age- and sex-matched controls with normal
renal function, cardiovascular morbidity and mortality are
excessive in patients with end-stage renal disease (ESRD)
[1–3]. Arguably, patients with ESRD undergo accelerated
atherosclerosis [4–6], which is a consequence of deleteri-
ous qualitative and quantitative lipid abnormalities that
accompany renal insufficiency [7–9]. Common lipid abnor-
malities that are of potential clinical relevance for patients
with renal failure are: (1) diminished high density lipopro-
tein (HDL) cholesterol and apolipoprotein A1 concentra-
tions; (2) normal or elevated low density lipoprotein (LDL)
concentrations; (3) hypertriglyceridemia with increased
very low density lipoproteins (VLDL); and (4) increased
lipoprotein (a) [Lp(a)] concentrations [6–13]. However,
with the notable exception of Lp(a), which is an indepen-
dent risk factor for atherosclerotic vascular disease in
patients with normal renal function [14–18] and ESRD
[12], most investigators have had difficulty establishing a
correlation between the lipoprotein profile and cardiovas-
cular events in ESRD patients [1, 19, 20].
Reproductive hormones such as estrogen have a pro-
found influence on the lipoprotein profile of both men and
women. Supportive evidence for the role of sex hormones
in lipid metabolism is derived from the observation of
gender differences in LDL and HDL levels with age [21,
22], the effect of the menstrual cycle on plasma LDL and
HDL concentrations [23, 24], and the effect of oral estro-
gens or progestins on the lipoprotein profile of men with
prostate cancer and postmenopausal women [25–29]. For
example, postmenopausal women have higher total and
LDL cholesterol concentrations, and lower HDL choles-
terol levels, than premenopausal women. Postmenopausal
women also have an increased rate of cardiovascular
events. The deleterious lipid profile and cardiovascular
outcome has been ascribed to the menopausal loss of
estrogen [20, 21, 30, 31]. In contrast, postmenopausal
women receiving estrogen replacement therapy have half
the relative risk of death due to cardiovascular disease as
do postmenopausal women who do not use estrogen. Some
investigators have advocated that the cardiovascular risk
Key words: cardiovascular disease, lipoproteins, cholesterol, estrogen,
lipids, end-stage renal disease, menopause.
Received for publication January 13, 1998
and in revised form April 22, 1998
Accepted for publication April 23, 1998
© 1998 by the International Society of Nephrology
Kidney International, Vol. 54 (1998), pp. 1344–1350
1344
reduction from estrogen replacement therapy is a conse-
quence of their effect on the deleterious lipoprotein profile
of being postmenopausal [32–34]. Specifically, estrogen
decreases LDL cholesterol by augmenting hepatic LDL
catabolism. HDL cholesterol is increased, especially HDL2.
Other quantitative and qualitative effects of estrogen in-
clude: increases in apolipoprotein A1 in HDL, but not A2;
increased triglyceride in VLDL; and reduced Lp(a), both
total and isoform specific [20, 25, 27].
It is unclear how vigorously to treat hyperlipidemia in
ESRD [6–8]. The frequency and severity of complications
associated with the long term use of some conventional
lipid lowering agents in patients with ESRD may render
their preemptive, routine use unwise [8]. Based on the
effects of estrogen replacement therapy on the concentra-
tions and metabolism of plasma lipoproteins in healthy
postmenopausal women, the correction in the profile of
lipoproteins is remarkably selective for the pathobiologic
pattern of lipid abnormalities seen in patients with ESRD.
Therefore, the use of estrogen replacement may be a novel
preemptive pharmacological intervention for the lipid ab-
normalities in women with ESRD. We structured this study
to address the hypothesis that estrogen replacement ther-
apy will favorably improve the lipoprotein profile in post-
menopausal women with ESRD undergoing maintenance
hemodialysis.
METHODS
This study was approved by the Human Research Com-
mittee of the Brigham and Women’s Hospital. All subjects
provided informed consent. Eligible subjects were women
$ 45 years old who had undergone hemodialysis for $ six
months, and no menstrual periods for $ one year. Inclusion
criteria were stable hematocrit $ 22%, normal hepatic
transaminases, and a follicle stimulating hormone greater
than 40 IU/ml. Exclusion criteria were a history of a
cerebrovascular accident, breast cancer, or current diabetes
mellitus requiring insulin therapy. Neither baseline lipid
nor lipoprotein abnormalities were used as entry criteria
for study participation. No patient was on estrogen replace-
ment therapy for six weeks prior to entry into the study.
Study protocol
All subjects underwent an initial history and physical
examination, including a screening mammogram. Seven
subjects entered a lead-in study evaluating the estradiol
levels attained on 1 mg oral estradiol daily for four weeks.
Because of concerns about the achievement of excessive sex
hormone levels, and a desire to minimize patient risks
secondary to excessive estrogen exposure, the lead-in study
was performed to assess the impact of a lower dose of
estrogen replacement therapy. After completing the four
week lead-in study, the subjects took medroxyprogesterone
acetate, 10 mg daily for one week and then underwent a
four week wash-out period. Medroxyprogesterone acetate
was included in this and the subsequent protocol to coun-
teract the uterine effects of unopposed estrogen stimula-
tion. The dose and duration of medroxyprogesterone ace-
tate therapy were conventional [25]. Based on these results,
thirteen subjects entered a double-blinded cross-over study
using oral micronized estradiol (2 mg) and a placebo
packaged in identical blisterpacks (supplied by Mead-
Johnson, Bristol Myers-Squibb). The women were initially
randomized to receive estrogen daily (or placebo) for eight
weeks, and after a wash-out period of four weeks, they
received the other therapy for eight weeks. Prior to receiv-
ing the first intervention, subjects who had not participated
in the lead-in study took medroxyprogesterone acetate, 10
mg daily for one week, and then began the first treatment
arm four weeks later. After eight weeks of treatment with
estrogen or placebo, all subjects took medroxyprogesterone
acetate, 10 mg daily for one week. Fasting blood samples
were obtained: (1) two days during the week prior to the
first intervention (estrogen or placebo), baseline samples,
(2) two days during the fourth week of the intervention, and
(3) three days during the last (eighth) week of the inter-
vention. After completion of the second treatment arm,
women with intact uteri took medroxyprogesterone ace-
tate, 10 mg daily for one week.
Blood drawing, sample processing, and assays
All blood samples were drawn from the hemodialysis
angioaccess at the time of routine predialysis blood drawing
with the subject fasting overnight. Samples were refriger-
ated, centrifuged at 2,500 rpm, aliqotted, and stored at
270°C. Estradiol was assayed using the immunofluorescent
Delphia system (Wallac, Gaithersburg, MD, USA). The
intraassay coefficient of variation for estradiol concentra-
tion is 10% from 0 to 99 pg/ml, 4.5% from 100 to 299 pg/ml,
and 2.7% at $ 300 pg/ml. The interassay coefficient of
variation is 4.6% from 0 to 300 pg/ml, 2.7% from 301-1000
pg/ml and 5.3% at .1000 pg/ml. There is ,1% cross-
reactivity with estrone. Estrone was assayed by radioimmu-
noassay using a commercial kit from Wein (Succasunna,
NJ, USA). The lower limit of sensitivity is 20 pg/ml. At
mean estrone levels of 80, 202 and 466 pg/ml the mean
intraassay coefficients of variation are 8.4%, 5.6%, and
6.2%, respectively. At mean estrone levels of 53, 205 and
497 pg/ml, the mean coefficients of variation were 13.5%,
5.6% and 2.6%, respectively. Sex hormone binding globulin
(SHBG) and serum albumin concentrations (BCG method)
were measured by conventional means. Estrone, albumin
and SHBG concentrations were measured on samples
pooled from the three samples drawn the last week of each
eight week treatment arm.
Blood samples from each subject were analyzed in one
batch at the end of the study in the Lipid Research
Laboratory of the Nutrition Department, Harvard School
of Public Health (Boston, MA, USA). This study was
standardized for cholesterol and HDL measurements as
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specified by the Centers for Disease Control and the
National Heart, Lung and Blood Institute. Samples from
each blood draw were measured separately, and the results
from each week (that is, results of three blood draws during
week 8) were averaged. VLDL was prepared from plasma
by overlaying 0.5 ml of 0.9% sodium chloride over 0.5 ml of
plasma, and spinning in a Beckman Type 25 rotor (Beck-
man Instruments, Palo Alto CA, USA) at 25,000 rpm for 16
hours. The VLDL fraction was separated from the LDL
and HDL fractions by tube slicing. HDL and HDL3 were
sequentially separated by precipitation with dextran sulfate
and magnesium chloride [35]. HDL2 was obtained by
subtraction of HDL3 from the total HDL. Cholesterol and
triglycerides were measured with enzymatic reagents and
quantified photometrically using a COBAS Mira Plus auto-
analyzer (Roche Diagnostics Systems, Belleville, NJ, USA).
Cholesterol, VLDL, the combined LDL and HDL frac-
tions, HDL and HDL3 were measured in whole plasma.
Triglycerides and apolipoprotein B were measured in
whole plasma and in the VLDL fraction. Apolipoprotein B,
apolipoprotein A1 and Lp(a) were measured by immuno-
turbidimetry with rabbit antiserum, [36] obtained from
Incstar (Stillwater, MN, USA) using the COBAS Mira Plus
auto-analyzer. The coefficients of variation for blinded
control specimens were as follows: 2.4% for cholesterol,
3.3% for HDL cholesterol, 2.8% for HDL3 cholesterol,
2.2% for apolipoprotein A1, 2.0% for apolipoprotein B,
and 3.0% for Lp(a).
Statistical analysis
Duplicate measurements were averaged and weighted as
a single test. Pre- and post-estrogen exposure lipoprotein
and hormone parameters were compared using the Wil-
coxon rank sum test. Comparisons were considered statis-
tically significant at P , 0.05. Non-parametric tests, like the
Wilcoxon rank sum, tend to be far more conservative with
regard to type I error than corresponding parametric tests
(such as, Student’s t-test). Analyses were conducted using
SAS (The SAS Institute, Cary, NC, USA).
RESULTS
The principal rationale for the lead-in study of four
weeks with 1 mg micronized oral estradiol daily was to
assess its impact on estrogen levels and to minimize patient
risks secondary to excessive estrogen exposure, not as an
intervention to effect the lipoprotein profile. Seven subjects
received 1 mg oral estradiol daily. One subject withdrew
because of ill health during fasting prior to blood sampling
at the time of hemodialysis. The remaining six subjects
completed the lead-in study, and three of these women
participated and completed the blinded, crossover portion
of the study. Thirteen subjects total were randomized to the
blinded crossover trial, but serum samples from one subject
were not able to be analyzed because of a handling mishap.
Twelve subjects completed the study. One subject withdrew
because she underwent cadaveric renal transplantation
during the trial. Another subject experienced vaginal bleed-
ing due to a benign vaginal lesion that was uneventfully
excised; she completed the study. Demographic informa-
tion on the 11 subjects who completed the trial is provided
in Table 1. Their mean age was 61.4 6 2.7 years (6 SEM);
eight of the women were African American, one was
Hispanic, and two were white. Two women had non-insulin
dependent diabetes mellitus.
Lipoprotein profiles
Lipoprotein and estradiol measurements were obtained
from the six women who completed the preliminary inter-
vention trial during which they ingested 1 mg estradiol daily
for four weeks. Table 2 provides the change in the lipid
profile for these subjects. During the period of estradiol
ingestion, estradiol levels increased approximately 4.5-fold.
In parallel, total cholesterol, total HDL cholesterol, and
the HDL2 cholesterol fraction increased significantly. No
significant change was observed in triglycerides.
Hormonal parameters from the placebo controlled,
cross-over intervention trial are provided in Table 3.
Higher estradiol levels were achieved with 2 mg per day of
estradiol, in comparison to 1 mg daily. In comparison to
eight weeks of placebo therapy, statistically significant
increases in estradiol, its metabolite estrone, and the
Table 1. Demographic profile of subjects completing randomized trial
Subject
Age
years Etiology of ESRD
Length
of renal
replacement Rx
years
Estimated
dry weight
kg
1 53 hypertension 4 59
2 62 polycystic kidney disease 2 54.5
3 56 hypertension 23 63
4 72 hypertension 0.7 55.5
5 45 focal glomerulosclerosis 0.5 70.5
6 59 hereditary nephritis 9.5 70
7 65 diabetes mellitus 0.5 66.4
8 75 diabetes mellitus 1.3 82
9 63 unknown 3.0 56.5
10 70 hypertension 10 57.5
11 58 hereditary nephritis 0.5 66.5
Table 2. Hormonal and lipid parameters with four weeks of estradiol
Baseline
value
Value at
week 4 P value
Estradiol pg/ml 21 6 6 91 6 19 0.002
Total cholesterol mg/dl 222.7 6 29.9 247.0 6 32.7 0.001
Total HDL cholesterol mg/dl 46.5 6 4.9 55.6 6 5.5 0.029
LDL cholesterol mg/dl 45.5 6 7.3 43.4 6 7.2 0.549
HDL2 cholesterol mg/dl 8.9 6 2.8 12.8 6 4.1 0.052
HDL3 cholesterol mg/dl 37.6 6 3.7 42.8 6 2.8 0.087
Triglycerides mg/dl 227.4 6 36.3 217.2 6 36.3 0.549
Abbreviations are: LDL, low density lipoprotein; HDL, high density
lipoprotein.
Results are from six women receiving 1 mg per day of estradiol
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steroid-inducible SHBG were observed. Total HDL choles-
terol concentration increased in all subjects (Table 4 and
Fig. 1A). The increase of the mean values was 16.1%. Total
HDL cholesterol concentration increased from 52.2 6 19.4
mg/dl after placebo treatment to 60.6 6 19.6 mg/dl
(mean 6 SEM; P 5 0.002) following estradiol. The fraction
of HDL that accounted for the majority of the increase in
total HDL cholesterol was HDL2, which increased by
28.6% (P 5 0.046), whereas HDL3 cholesterol increased by
9.2%, a difference that did not reach statistical significance
(Table 4). With eight weeks of estradiol treatment, nine of
eleven women had increases in HDL2 cholesterol, and
eight women had increases in HDL3 cholesterol. LDL
cholesterol was unchanged for all subjects. There was no
significant association between the increase in HDL cho-
lesterol concentration and the concentrations of estradiol
or estrone. Apolipoprotein A1 increased by 24.6%, from
149.7 6 42.2 mg/dl to 186.6 6 39.1 mg/dl (P 5 0.0002).
Lp(a) was not significantly affected. Although the total
triglyceride concentration increased by 15.8% with daily
estradiol ingestion, the elevation compared to placebo
therapy was not significant.
DISCUSSION
Low HDL cholesterol concentrations are often, but not
uniformly observed in patents with chronic renal insuffi-
ciency, especially the HDL2 subfraction [37]. In the present
study, HDL cholesterol concentrations were within the
normal range. However, oral micronized estradiol in-
creased the serum total HDL cholesterol concentration by
an average of 8.4 mg/dl (16.1%), and increased apolipopro-
tein A1 by 24.6% compared with placebo treatment. Previ-
ous studies in patients with normal renal function suggest
that comparable increases in total HDL cholesterol can be
expected to decrease the risk of cardiovascular disease by
approximately 50% [38]. Even the 1 mg daily dose of
estradiol that was administered during the lead-in portion
of the current intervention trial increased HDL by 20%
after only four weeks. This is a level of response that would
also be expected to significantly decrease the incidence of
coronary artery disease. The triglyceride concentration was
not significantly increased by low dose estrogen replace-
ment therapy, but the lack of statistical significance may be
due in part to the small sample size in the setting of large
inter-individual variations in triglyceride concentrations.
The mean triglyceride levels in this subject group were not
out of the normal range, however. Hypertriglyceridemia
Table 3. Hormonal levels with eight weeks of therapy
Hormonal parameter
Intervention
Placebo Estradiola
P
value
Reference
range
Estradiol pg/ml 19 6 4 194 6 67 0.024 ,30
Estrone pg/ml 24 6 6 684 6 186 0.006 15–55
Albumin mg/dl 4033 6 118 3947 6 84 0.220 3900–5400
Sex hormone binding
globulin nmol/liter
61 6 7 94 6 9 0.0006 8–85
a Results are from eleven women receiving 2 mg per day of estradiol
Table 4. Serum lipoprotein levels with eight weeks of therapy
(mean 6 SEM)
Lipoprotein mg/dl
Intervention
Placebo Estradiola
P
value
Reference
range
VLDL
Cholesterol 22.6 6 19.6 24.2 6 20.8 0.643 ,20
Triglycerides 78.7 6 62.4 92.4 6 81.2 0.319 NEb
Apolipoprotein B 17.0 6 13.4 17.9 6 13.5 0.647 NE
LDL
Cholesterol 131.0 6 56.2 129.1 6 49.1 0.837 ,130
Apolipoprotein B 55.9 6 21.7 57.1 6 17.7 0.761 NE
HDL
Cholesterol 52.2 6 19.4 60.6 6 19.6 0.002 .35
HDL2
Cholesterol 18.5 6 12.7 23.8 6 15.9 0.045 NE
HDL3
Cholesterol 33.7 6 9.7 36.8 6 8 0.106 NE
Apolipoprotein A1 149.7 6 42.2 186.6 6 39.1 0.0002 115–220
Total cholesterol 205.4 6 71.8 211.4 6 56.6 0.538 ,200
Total triglycerides 164.1 6 96.2 190.1 6 103.4 0.176 ,130
Lp(a) 36.8 6 33.3 36.8 6 29.2 0.987 NE
a Each of eleven women received 2 mg per day of estradiol
b NE, normal range has not been established
Fig. 1. Individual total HDL cholesterol concentration (mg/dl) in 11
women with completing eight weeks of placebo and with eight weeks of
estradiol (2 mg per day).
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seen in hemodialysis patients is thought to be due to
defective triglyceride removal secondary to inhibition of
lipoprotein lipase activity [39]. The doses of estrogen used
in the intervention reported herein had no significant effect
on plasma Lp(a) or LDL cholesterol levels. Insufficient
power (that is, large type 2 error) is an important consid-
eration in interpreting any apparent lack of effect, since
size (and scatter) may limit the ability to detect differences
among groups.
Previous investigations have demonstrated that basal
estradiol concentrations as well as those attained after oral
estradiol ingestion are greater in postmenopausal women
with ESRD than in body-mass index matched controls,
probably due to decreased clearance of endogenous and
exogenous estradiol [40]. Although no adverse effects were
observed in the present study, a larger number of subjects
with a longer period of estrogen ingestion is needed to
validate this observation. Because of the absence of corre-
lation between the increase in estradiol and estrone con-
centrations and the increase in HDL cholesterol, it is
unlikely that extraordinarily high sex hormone concentra-
tions are needed to improve the HDL:LDL ratio. In that
the biologic effect of 2 mg daily of oral estradiol is not
much different than that observed with 1 mg daily, but
blood estradiol levels were lower with 1 mg daily oral
estradiol (194 vs. 91 pg/ml for 2 vs. 1 mg/day, respectively),
we advocate the use of the lower estradiol dose for future
clinical intervention trials. This will minimize the risks
associated with higher hormone levels.
Not all ESRD patients have abnormal lipoprotein pro-
files. Moreover, the incidence of death due to cardiovascu-
lar disease in the ESRD population is very high regardless
of the lipoprotein profiles found. Therefore, other factors
may contribute to this excessive cardiovascular mortality,
and/or the lipoprotein profile is an incomplete surrogate of
the deleterious effect of hyperlipidemia in ESRD. Simi-
larly, in healthy postmenopausal women, estrogen replace-
ment therapy is associated with a decrease in the risk of
death due to cardiovascular disease by 50% [41]. However,
this effect appears to be partly independent of the individ-
uals’ lipoprotein profile, and is much greater than would be
predicted by the change in the lipoprotein profile alone.
Furthermore, based on longitudinal studies of healthy
women with angiographically demonstrable coronary artery
stenosis, simply having received estrogen replacement ther-
apy at any time reduces the risk of death by 10 to 27% in
comparison to nonusers [42]. Therefore, although the
change in the lipoprotein profile was moderate in this study
as in studies of women with normal renal function, a similar
experience in postmenopausal women with ESRD may
result in substantial benefit with reductions in deaths due to
cardiovascular disease.
Many treatments for hyperlipidemia have been evaluated
in ESRD including gemfibrozil [43], probucol [44], pan-
tethine [45], and LDL-pheresis [46]. Lovastatin and simva-
statin treatment in ESRD patients on hemodialysis in-
creases HDL cholesterol and apolipoprotein A1 and
decreases triglycerides [47]. However, whether these
changes reduce the incidence of heart disease has not been
established. Furthermore, consideration must be made of
the major side effects associated with the use of many of the
conventional lipid lowering agents. For example, HMG
CoA reductase inhibitors have major routes of renal excre-
tion. When used alone, but especially in combination
therapy with other lipid lowering agents, there is an in-
creased incidence of rhabdomyolysis and elevated hepatic
transaminases. Similar side effects have been observed with
gemfibrozil, as well as enhanced sensitivity to oral antico-
agulants. Probucol is relatively unsafe in patients with
conduction system abnormalities. Some data suggests that
modification of dietary fat can significantly decrease tri-
glycerides in hemodialysis patients [48]. However, if eleva-
tions of HDL cholesterol seen with gemfibrozil decreases
cardiovascular risk [43], similar benefit may be achieved
from the use of estrogen replacement therapy with fewer
side effects. Added cardiovascular benefits from estrogens
include their ability to dilate coronary arteries [49], de-
crease coronary resistance [50], and increase coronary
perfusion.
The data presented herein indicate that the use of
estrogen replacement therapy results in increases of HDL
cholesterol and apolipoprotein A1 that are comparable to
those achieved in healthy postmenopausal women. In the
present study, baseline lipid or lipoprotein abnormalities
were not used as entry criteria. A principal reason for this
approach is that in this early intervention trial, we were
uncertain what benchmark abnormalities to use. Instead,
we elected to examine the effect of estrogen replacement
therapy on a random sample of postmenopausal women
with ESRD, as was done in a previous landmark trial in
healthy postmenopausal women [25]. Furthermore, the
strategy of including ESRD patients, indifferent of the
severity of their lipid abnormalities, permitted us to profile
the type and severity of baseline lipid and lipoprotein
derangements in a random sample of postmenopausal
women with ESRD. The findings reported herein may not
be reproducible in some postmenopausal women with an
alternative lipid or lipoprotein profile. It is unknown
whether patients with greater derangement in lipoprotein
parameters would achieve the same, greater, or lesser
effects with estrogen replacement as the subjects in the
present study. Furthermore, this study has not addressed
the ultimate question of whether improvements in lipopro-
tein parameters will lead to comparable reductions in
cardiac mortality. Larger clinical trials are needed to
answer these questions, and to determine whether estrogen
replacement therapy should be conventional care for post-
menopausal women with ESRD. In the design of future
trials with estrogen replacement therapy, consideration
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should be made of their potential to improve other comor-
bid conditions in postmenopausal women such as preven-
tion of estrogen-deficiency related osteoporosis [51, 52],
symptoms of urogenital atrophy [53], improved skin elas-
ticity [54] and decreased wrinkling [55], and a decreased
risk of Alzheimer’s disease [56–59]. In patients with ESRD,
platelet dysfunction is improved [60, 61]. These potential
benefits must be balanced against the possible increased
risks of breast cancer [62, 63], non-fatal venous thrombo-
embolism [64], and cholelithiasis [65]. The increase risk of
thromboembolic disease may be a consequence of the
increase in clotting factors observed with oral, but not
transdermal, estrogen replacement therapy [66, 67].
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